The domestic stem cell industry faces three major challenges [Figure]

Zyzhan guide: In recent years, stem cell technology and development has been favored by domestic and foreign capital markets. In the listed stocks listed on NASDAQ, the market value of stem cell concept stocks exceeds 30 billion US dollars. In China, the stem cell and regenerative medicine industry is one of the new high-tech bio-industries with the most potential for development in China. Accelerating the development of this industry is of great and practical significance for improving human living standards and benefiting human health.

According to estimates by relevant agencies, China's stem cell market is currently around 2 billion yuan. It is estimated that the income of China's stem cell industry will reach 30 billion in the next five years, with an average annual growth rate of 170%.

The domestic industry is facing three major challenges stem cell commercialization <br> <br> China to bear the brunt of stem cell research included in the national 863 and 973, stem cell research and the United States a few years ago to limit stem cell market, China has brought opportunities, many American experts Looking for cooperation with Chinese companies or research institutions, after more than a decade of development, China's stem cells have ranked the top ten in the world as a whole.

However, in the stem cell treatment market, although many units in China have initially tried to use stem cell therapy, and some cases have achieved very good results, but because the market is not yet mature, it has not been officially approved by the state, and there is a lack of industrialized products. . These problems have greatly limited the development of stem cell industrialization in China, especially in the stem cell treatment market. Therefore, China urgently needs to formulate standards, regulations and management methods suitable for the characteristics of stem cell technology to guide the healthy development of China's stem cell industry.

(1) immature technology, low level of commercial <br> within <br> worldwide, in the United States belong to one of the leading countries in the field more, but the Government of the United States National Institutes of Health (NationalInstitutesofHealth) believes that there are still important areas The technical barriers need to be overcome in a longer period of time. In terms of sales, in 2006, three biopharmaceuticals for the treatment of immune diseases such as rheumatoid arthritis, Enbrel (Anjin, fusion protein), Humira (Abbott, monoclonal antibody) and Remicade (Johnson Johnson, single The total sales of cloned antibody drugs was $8.5 billion, and its gross sales revenue accounted for a very low overall sales ratio at the time.

As far as China is concerned, some scientists have won excellent paper awards at an international conference, but most of them are oriented to applied basic research, which is farther away from commercialization. If hematopoietic stem cell therapy, bone marrow transplantation, etc. are included in the scope, then Chinese stem cell treatment is not a very strange term, but the standardization of stem cell therapy is relatively late. By 2009, the state has introduced relevant regulations, and there is basically no industrialized product. The large-scale marketization is still far away.

(2) the gray areas, the industry is not standardized <br> <br> the current number in the gray area of "stem cell therapy" is not uncommon in China, for example, has been the international media often refer to a domestic company was involved "Neural stem cell transplantation" treatment of more than 20 diseases such as cerebral palsy, cerebral infarction, type 2 diabetes, spinal cord injury, and amyotrophic lateral sclerosis. The authenticity of this type of treatment is questionable. The implementation of such treatments has not been officially approved by the state, and it is an irregular gray area.

Large (3) market demand and broad prospects <br> <br> is undeniable that the Chinese stem cell therapy market is increasing, according to the relevant information, experts predict that China's current stem cell therapy market annual growth rate of over 100%. Whether it is the admission criteria for clinical research, the outsourcing of stem cell research, or even the institutions associated with stem cell and regenerative medicine research services, it will have a huge market share in this industry chain. Therefore, in the early stage of the current development, early intervention in the stem cell research industry chain will be able to take the lead in the next round of the stem cell industry outbreak. In April 2006, the mesenchymal stem cell bank belonging to the National Engineering Research Center for Cell Products was completed in Tianjin. The only mesenchymal stem cell bank in China is dedicated to the development and production of stem cell products and provides services such as stem cell storage.

Toggles Hooks

Cam Latches,Hardware Latches,Toggles Hooks,Adjustable Toggle Latches

Ningbo Hengchieh Locking Technology Co., Ltd. , https://www.hengchieh.com